As JAK3 mutants are dependent on JAK1 signaling for their cellular transformation, it is possible to use both JAK1/JAK2 and JAK3‐selective inhibitors in JAK3 mutation–positive leukemia [11]. Here, JAK1 is linked to leukemia.